Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: ``excess of $38 million in distributions as its share``

``excess of $38 million in distributions as its share``

posted on Apr 17, 2006 06:50AM
And what`s their annual breakeven point?

Do you know what most companies have to generate in gross revenues to net out numbers in that neighborhood???

There will be new investors in light of performance and future potential at hand.

Per management: `` The nature of the process is such that it requires our patience because, as much as we and our shareholders might desire otherwise, the status and progress of negotiations must remain confidential, and license agreements are not consummated according to any regular or predictable schedule,`` he added. ``We remain optimistic about our outlook, and we remain focused on maximizing the long-term value of our business for the benefit of our shareholders,`` Pohl said.

Share
New Message
Please login to post a reply